Efficiency of long targeted therapy of paroxysmal night hemoglobinuria in real clinical practice

The modern pathogenetic methodof treatment of intravascular hemolysis inparoxysmal nocturnal hemoglobinuria (PNH)is the use of eculizumab, which is a humanized monoclonal antibody against the C5 component ofthe complement system. The analysis of 5 clinicalcases of patients with PNH who received long-term therapy with eculizumab in our clinic forthe period 2012-2017 is presented. Eculizumabshowed high efficacy in the long-term targetedcontrol of hemolysis in patients with PNH in thereal clinical practice.